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Abstract
Background: Post-therapeutic follow-up is essential to confirm cure and to detect early treatment failures in patients
affected by sleeping sickness (HAT). Current methods, based on finding of parasites in blood and cerebrospinal fluid (CSF)
and counting of white blood cells (WBC) in CSF, are imperfect. New markers for treatment outcome evaluation are needed.
We hypothesized that alternative CSF markers, able to diagnose the meningo-encephalitic stage of the disease, could also
be useful for the evaluation of treatment outcome.
Methodology/Principal findings: Cerebrospinal fluid from patients affected by Trypanosoma brucei gambiense HAT and
followed for two years after treatment was investigated. The population comprised stage 2 (S2) patients either cured or
experiencing treatment failure during the follow-up. IgM, neopterin, B2MG, MMP-9, ICAM-1, VCAM-1, CXCL10 and CXCL13
were first screened on a small number of HAT patients (n = 97). Neopterin and CXCL13 showed the highest accuracy in
discriminating between S2 cured and S2 relapsed patients (AUC 99% and 94%, respectively). When verified on a larger
cohort (n = 242), neopterin resulted to be the most efficient predictor of outcome. High levels of this molecule before
treatment were already associated with an increased risk of treatment failure. At six months after treatment, neopterin
discriminated between cured and relapsed S2 patients with 87% specificity and 92% sensitivity, showing a higher accuracy
than white blood cell numbers.
Conclusions/Significance: In the present study, neopterin was highlighted as a useful marker for the evaluation of the post-
therapeutic outcome in patients suffering from sleeping sickness. Detectable levels of this marker in the CSF have the
potential to shorten the follow-up for HAT patients to six months after the end of the treatment.
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Introduction
Sleeping sickness, also known as human African trypanosomi-
asis (HAT), is a neglected parasitic disease widespread in sub-
Saharan Africa where it mainly afflicts rural communities [1].
According to the most recent published data, 10’000 new cases
were reported in 2009 [2]. More than ninety percent of HAT cases
are caused by Trypanosoma brucei gambiense parasite, which is
responsible for a chronic disease in Western and Central Africa
[2]. Without treatment the disease progresses through two stages.
Immediately after infection the proliferation of the parasites in
blood and lymph, gives rise to the haemolymphatic first stage
(stage 1, S1). If stage 1 patients are not treated, the disease
progresses to the second meningo-encephalitic stage (stage 2, S2)
as a consequence of the penetration of the parasites into the
central nervous system (CNS) [2]. HAT patients need to be treated
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according to their stage. Thus, S1 patients should receive
pentamidine treatment, while S2 patients can be treated using
melarsoprol, eflornithine or NECT (nifurtimox-eflornithine com-
bination therapy) [3,4]. However, patients cannot be considered
cured immediately after treatment as parasites may persist in the
host and the disease may reappear later on [5] as a consequence of
treatment failure. To assess the efficacy of the treatment, patients
need to be followed for two years to detect relapses, or to confirm
recovery [6]. WHO still recommends 5 follow-up visits performed
at the end of the treatment (EoT) and at 6, 12, 18 and 24 months
after treatment [6]. Visits consist of clinical assessments, exami-
nation of blood and cerebrospinal fluid (CSF) for the presence of
trypanosomes and evaluation of the number of white blood cells
(WBC) in the CSF. Optimal criteria to detect relapses accurately
and early, when trypanosomes are not yet detectable, are being
investigated. Several studies have tried to determine a cut-off for
the number of WBCs, to predict relapses and to shorten the
follow-up to less than 24 months after treatment [5,7,8]. Recently,
an algorithm based on the CSF WBC count at 6 and 12 months
has been proposed and showed a high potential in shortening
patient follow-up as soon as 6 months after treatment [5,8].
However, the counting of WBC still has weaknesses, such as
limited specificity and reproducibility, as already highlighted for
the staging of HAT patients [9]. New surrogate markers to assess
the post-therapeutic outcome therefore represent an unmet need,
as highlighted by WHO [10,11].
Very few alternative markers in CSF have been evaluated so far.
These include DNA detection by PCR [12,13], IgM and
trypanosome specific antibodies, total proteins and the level of
the anti-inflammatory cytokine IL-10 [14]. However, when
assessed at 6 and 12 months after treatment, they showed lower
accuracy as outcome predictors compared to WBC.
We hypothesize that newly described CSF staging markers [15–
23], able to indicate the presence of the second stage of sleeping
sickness, could also indicate a reappearance of the infection in S2
patients after treatment. IgM, B2MG, CXCL13, CXCL10,
MMP-9, VCAM-1, ICAM-1 and neopterin were first tested on
a small cohort of HAT patients followed after treatment to carry
out a preliminary selection of molecules with highest accuracy as
outcome predictors. Markers with the highest accuracy (neopterin
and CXCL13) were further validated on a larger number of
patients and compared to WBC to assess the treatment outcome.
Methods
Ethics statement
The THARSAT study, from which patients originated, was
approved by the Ministry of Health of the Democratic Republic of
the Congo and by the Commission for Medical Ethics of the
Institute of Tropical Medicine Antwerp, Belgium (reference
04441472). All patients, or their legal representatives, gave written
informed consent before enrolment. All patients had the possibility
to withdraw from the study at any moment.
Patients
The present study was designed into two parts: a first screening
of 8 markers on a small population, followed by the verification of
the two most promising markers on a larger cohort.
All patients were enrolled by either active or passive case finding
in the Democratic Republic of the Congo as part of the
THARSAT study [8]. Inclusion and exclusion criteria are
reported elsewhere [8].
All patients had parasitologically confirmed HAT, either as
primary cases (no previous HAT treatment) or as secondary cases
(previously treated for HAT). Stage determination was performed
through CSF examination for number of leukocytes and presence
of parasites following modified single centrifugation [24]. Stage
was defined according to WHO guidelines, i.e. stage 1 when WBC
#5 cells/mL and absence of parasites, stage 2 when WBC.5 cells/
mL and/or parasites detected in CSF [6]. Patients were treated
according to their stage as reported by Mumba Ngoyi et al. [8].
After treatment, patients were followed up with visits planned at
the end of the treatment (EoT) and at 3, 6, 12, 18 and 24 months
after treatment. Blood and CSF examinations were performed at
each follow-up visit and outcome was determined as recom-
mended by WHO [8,10]. Briefly, cured patients were defined
based on absence of trypanosomes during the follow-up and CSF
WBC #20/mL at 24 months for stage 2, or CSF WBC #5/mL for
stage 1. Confirmed relapses were diagnosed following the finding
of parasites in CSF at any follow-up visit. Probable relapses were
diagnosed following an increased count of WBC (more than 30
WBC/mL compared to the lowest number of WBC obtained
during the previous FU examinations) and/or aggravation of
neurological signs, or WBC.20/mL at 24 months [8]. Patients
classified either as confirmed or probable relapses were considered
as treatment failures.
The patients investigated in the present study were selected
among the 360 participants of the THARSAT study [8], after
exclusion of those who died prior or during the follow-up, relapses
of early stage patients, patients lost during the follow-up or for
whom 2 or more interim follow-up visits were missing. Further-
more, patients whose diagnosis of relapse was based on the finding
of parasites in blood (n= 8) were also excluded, as they could
potentially represent re-infection cases.
The screening cohort comprised S1 (n = 19) and S2 (n= 78)
primary cases. All S2 patients included in the screening cohort
received melarsoprol treatment and only cases of treatment failure
(i.e. S2 relapse) defined as confirmed relapse were chosen. Selected
cured and relapsed S2 patients were matched for age and sex.
Characteristics at baseline, i.e. observed at the moment of the
diagnosis and before the treatment, of patients included in the
screening cohort are reported in Supporting Table S1.
The verification cohort (n = 242) comprised all patients of the
THARSAT study considered eligible for the present study and for
whom enough CSF sample volume was available to perform all
the analyses. Eighty six patients were included in both screening
and verification cohort. The characteristics at baseline of the
Author Summary
The reduction of the number of lumbar punctures
performed during the follow-up of patients affected by
sleeping sickness (HAT) is considered a research priority.
Follow-up, consisting of the examination of cerebrospinal
fluid (CSF) for presence of parasites and for the number of
leukocytes, is necessary to assess treatment outcome.
However, diagnosis of treatment failure is still imperfect
and WHO encourages improvements in defining criteria.
Many studies have attempted to standardize actual
methods and to define a cut-off for the number of white
blood cells in CSF to define relapses, while only few have
proposed alternatives to current practice. Here we show
that neopterin, already proven to be a powerful marker for
staging T. b. gambiense HAT, is also useful in evaluating
post-therapeutic outcome. The measurement of neopterin
concentration in CSF during the follow-up may allow
reduction in the number of lumbar punctures from five to
three for the majority of cured patients.
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verification cohort are reported in Table 1. More details on the
verification cohort are reported in Supporting Figure S1.
Immunoassays
Cerebrospinal fluid levels of neopterin (Brahms, Thermo Fisher
Scientific, Germany), IgM (ICL, OR, USA), B2MG (Calbiotech,
CA, USA) and CXCL13 (R&D Systems, UK and RayBiotech,
GA, USA), were measured using commercially available ELISA
assays. The levels in CSF of CXCL10, MMP-9, ICAM-1 and
VCAM-1 were measured using multiplex bead suspension assays
(R&D Systems, UK).
All assays were performed according to manufacturer’s instruc-
tions and the inter-assay variability was evaluated using quality
controls (coefficient of variation - CV,20%). A limit of detection
(LOD, corresponding to the mean measured concentration for the
lowest standard less 2 standard deviations) was calculated for each
assay. To all outliers (#LOD) a value corresponding to the mean
of LODs divided by 2 was assigned.
Statistical analysis
All statistical analyses were performed using IBM SPSS
Statistics version 20.0.0 (IBM, NY, USA) and STATA version
11.0 (StataCorp LP, TX, USA). Receiver operating characteristic
(ROC) curves, area under the ROC curve (AUC), corrected
partial AUC (pAUC), sensitivity (SE) and specificity (SP) were
computed using the pROC package for S+ version 8.1 (TIBCO,
Software Inc.).
All statistical tests were two tailed and significance level was set
at 0.05. Comparison between two groups was performed with the
Mann-Whitney U test for independent variables or using the
Wilcoxon signed rank test for dependent variables. The accuracy
of the markers in discriminating between cure and relapse was
evaluated considering only stage 2 patients.
First analysis – screening. ROC analysis was performed to
assess the accuracy of the markers in discriminating between cured
and relapsing patients. The AUC and the cut-off corresponding to
the highest combination of specificity and sensitivity were
calculated. Comparison was done between the levels of the
markers measured in S2 patients at the moment of the relapse
taking cured S2 patients at matched time points. The two best
markers were selected for further analyses.
Second analysis – verification. Baseline risk factors, i.e.
pre-treatment, for relapse were assessed using logistic regression
and calculating the relative risk, prior and after adjustment for
treatment. The following baseline variables were investigated for
their association with an increased risk of treatment failure: sex,
age, treatment, secondary cases, incomplete treatment, presence of
parasites in CSF, number of WBC in CSF, presence of
neurological signs and CSF concentrations of neopterin and
CXCL13. The threshold in concentration of the two markers was
determined using ROC curves and comparing their baseline levels
in the two categories of late stage patients (cured and relapsed).
The accuracy for the prediction of treatment outcome was
evaluated for neopterin, CXCL13 and WBC at three, six and
twelve months after treatment. Eighteen and 24 months were not
tested due to the low number of patients experiencing a relapse
later than 12 months after treatment in the THARSAT study. For
each marker and at each time point of the follow-up a highly
sensitive cut-off was selected within an area under the ROC curve
comprised between 90 and 100% sensitivity (partial AUC - pAUC)
[25]. Positive and negative likelihood ratios (LR+ and LR2,
respectively) were calculated to better evaluate the association of
the levels of the markers and the final outcome at the 3 time points
of follow-up considered [26].
Table 1. Characteristics at baseline of the verification cohort.
S1 cured (n=21) S2 cured (n =114) S2 relapsed* (n =107)
Demography
Sex, F (n){ 14 (66.7%) 28 (24.6%) 33 (35.3%)
Age, years [mean 6 SD]{ 37.3 [613] 34 [612.4] 34.3 [612.4]
Pre-treatment CSF examination
Trypanosome positive, n 0 104 100
WBC/mL (median, range) 3 [1–5] 213 [2–1940] 267 [8–2064]
Neurological signs
Absent 13 15 13
Present 8 99 94
Treatment
P 21 0 0
E 0 42 2
M 0 40 99
M-E 0 1 0
M-N 0 31 6
Secondary case, nI 0 66 9
*n = 27, probable relapse.
{No significant difference between S2 cured and S2 relapsed, Fisher’s exact test.
{No significant difference between S2 cured and S2 relapsed, Mann-Whitney U test.
ISecondary case: patients already treated once for HAT.
P: pentamidine treatment; E: eflornithine treatment; M: melarsoprol treatment; M-E: combination of melarsoprol and eflornithine; M-N: combination of melarsoprol and
nifurtimox. More details on treatment regimens are reported in [8].
doi:10.1371/journal.pntd.0002088.t001
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Results
First analysis - screening
The first analysis consisted in the evaluation of IgM, B2MG,
CXCL10, CXCL13, MMP-9, VCAM-1, ICAM-1 and neopterin
on a cohort of 97 patients.
According to the AUC, neopterin and CXCL13 showed the
highest accuracy in discriminating S2 cured and S2 relapsed
patients (Table 2). Neopterin showed a higher AUC, and both
neopterin and CXCL13 showed higher sensitivity than the
counting of leukocytes.
The ability of neopterin and CXCL13 in following the disease
progression in the different categories of patients was further
confirmed through the kinetic profiles, where an increased
concentration of the two markers in relapsing patients was
highlighted (Supporting Figure S2).
Second analysis - verification
Pre-treatment evaluation of the markers. Neopterin and
CXCL13 were investigated on a larger population comprising 242
patients (Table 1, Supporting Figure S1). Baseline characteristics
of S2 patients, cured and relapsed, were first analysed to evaluate
whether they could already represent a risk of treatment failure
(Table 3). An increased risk of relapse was associated with the
received treatment and with the condition of being a primary case,
i.e. never treated before for HAT. As these two conditions are
strictly associated (primary cases were preferentially treated with
melarsoprol), new relative risks were calculated after adjustment
for treatment. This analysis highlighted an increased risk of relapse
for patients presenting parasites in the CSF and a high count of
WBC ($100/ml) at diagnosis.
At the time of the diagnosis, i.e. before treatment, the levels of
neopterin and CXCL13 were higher in S2 patients, cured or
relapsed, compared to S1 (p value,0.0001, Kruskal-Wallis test,
followed by post-test paired comparison). Only neopterin was able
to significantly discriminate (p,0.05) between cured S2 patients
and relapsed S2 patients already at baseline with AUC of 60%
(52.8–67.74 95% CI), while CXCL13 and WBC showed AUC of
55% (49.2–61, 95%CI) and 56.8% (49.3–64.4), respectively.
However, no significant differences were observed between the
ROC curves (DeLong’s test for two correlated ROC curves) (data
not shown).
When the best cut-offs for discrimination between S2 cured and
relapsed patients at baseline (neopterin 261.6 nmol/L and
CXCL13 1734.1 pg/mL) were used to dichotomize the popula-
tion, patients presenting high baseline levels of the markers were
associated to a significantly higher risk for treatment failure
(Table 3).
Evolution of the markers after treatment. A significant
decrease in CSF concentration of neopterin, CXCL13 and white
blood cells was observed in all S2 patients after treatment (p
value,0.0001, Wilcoxon signed rank test for paired samples) (data
not shown).
The evolution of the two markers and of WBC during further
follow-up of HAT patients is represented in Figure 1. The levels of
neopterin, CXCL13 and of WBC in S1 cured patients remained
constantly lower than in S2 patients. In late stage patients
confirmed to be cured at the end of the follow-up neopterin,
CXCL13 and WBC reached levels comparable to those observed
in S1 patients cured already 3 months after treatment (Figure 1).
In those patients experiencing a relapse, the levels of the two
markers and of WBC, after having decreased following treatment
administration, started to increase at 3 months after treatment
when 43 patients out of 105 already had a relapse or a probable
relapse. Similarly, higher median concentration of neopterin and
CXCL13 were observed in relapsing patients 6 and 12 months
after treatment compared to cured S2 patients.
ROC curves were built to assess the performance of neopterin,
CXCL13 and WBC count in discriminating between cured S2
patients and S2 patients having a relapse 3, 6 and 12 months after
treatment. Partial AUC (pAUC) between 90 and 100% of
sensitivity and the best cut-off within this area were calculated
(Table 4). When measured in the CSF taken 3 months after
treatment, neopterin and CXCL13 showed accuracy comparable
to the one of WBC. However, six months after treatment,
neopterin was a better predictor of the outcome than both
CXCL13 and WBC with a negative likelihood ratio ,0.1
indicating a strong correlation between the levels of this marker
and the ruling out of cured patients. At this time point, neopterin,
at a CSF concentration of 28 nmol/L was able to correctly classify
as cured 97 out of 111 patients, with only 5 false negatives.
Similarly, a WBC count of ,11 cells/mL could correctly predict
90 out of 111 cured patients with 6 false negatives, while CXCL13
could only predict 71 out of 111 cured patients.
Table 2. Performance of the markers on the screening cohort.
Marker AUC% (95%CI) Cut-off SP% (95%CI) SE% (95%CI)
Neopterin [nmol/L] 99.1 (97.7–100) 64.4 100 (100–100) 92.3 (82.1–100)
CXCL13 [pg/mL] 94.0 (88.9–99.2) 125.5 84.6 (71.8–94.9) 92.3 (82.1–100)
ICAM-1 [ng/mL] 93.2 (87.0–99.4) 2.1 92.3 (82.1–100) 87.2 (76.9–97.4)
CXCL10 [pg/mL] 90.0 (83.6–98.2) 2308.4 84.6 (71.8–94.9) 89.7 (79.5–97.4)
B2MG [ng/mL] 89.2 (81.4–97.1) 2486.5 94.9 (87.2–100) 76.9 (64.1–89.7)
MMP-9 [pg/mL] 88.8 (80.8–96.9) 814.8 84.6 (71.8–94.9) 87.2 (76.9–97.4)
VCAM-1 [ng/mL] 86.2 (77.4–95) 38.5 94.9 (87.2–100) 69.2 (53.9–82.1)
IgM [mg/mL] 81.2 (71.6–90.8) 75.9 66.7 (51.3–79.5) 87.2 (76.9–97.4)
WBC (Cells/mL) 96.9 (93.9–100) 44.5 94.9 (87.2–100) 89.7 (79.5–97.4)
Number of patients: 39 S2 relapsed vs. 39 S2 cured.
SP%: specificity %; SE%: sensitivity%; 95%CI: 95% confidence interval.
The reported cut-off corresponds to the best combination of specificity and sensitivity obtained for each marker.
doi:10.1371/journal.pntd.0002088.t002
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Finally, twelve months after treatment neopterin showed strong
power to rule in (LR+ 35) and to rule out (LR2 0.06) S2 patients.
At a concentration of 41.4 nmol/L, it could correctly predict cure
in 97% (93.6–100 95%CI) of cured patients with only 1 relapsing
patient miss-classified, compared to the 93% predicted by WBC
(87.3–97 95%CI). CXCL13 showed again a lower accuracy, being
able to predict cure in 87% of cured patients (80.9–92.7% CI)
(Table 4).
Discussion
The long post-therapeutic follow-up for patients affected with
sleeping sickness is a major limitation in the management of HAT
patients [6]. A gold standard to detect treatment failures is still
missing [10]. New tools to achieve a better evaluation of treatment
outcome, in terms of early detection of relapses and reduction of
the time of follow-up are absolutely needed [11]. The reduction of
Table 3. Baseline risk factors for treatment failure in late stage patients.
Treatment failure Unadjusted Adjusted for TT
Baseline variable n/N RR p value RR p value
Sex
F 33/61 1 1
M 74/160 0.85 0.28 0.88 0.31
Age
,25 27/55 1 1
25–39 43/94 0.93 0.69 1 0.99
.40 37/72 1.05 0.80 0.91 0.54
Treatment
E 2/44 1
M 99/139 15.67 ,0.0001
M-E 0/1 0.00 ,0.0001
M-N 6/37 3.57 0.11
Secondary case
No 98/144 1 1
Yes 9/77 0.17 ,0.0001 0.94 0.90
Incomplete treatment
No 92/197 1 1
Yes 15/24 1.34 0.10 1 0.96
Parasites in CSF
T2 7/17 1 1
T+ 100/204 1.19 0.56 1.83 0.04
CSF WBC/mL
,100 17/46 1 1
100–199 26/50 1.40 0.15 1.64 0.02
200–399 32/69 1.25 0.39 1.52 0.04
$400 32/56 1.54 0.05 1.32 0.18
Neurological signs
NS2 12/27 1 1
NS+ 95/194 1.1 0.67 1.28 0.24
Neopterin [nmol/L]
#261.6 35/96 1 1
.261.6 72/125 1.58 0.003 1.75 ,0.0001
CXCL13 [pg/mL]
#1734.1 17/50 1 1
.1734.1 90/171 1.55 0.04 1.55 0.02
TT: treatment; E: eflornithine treatment; M: melarsoprol treatment; M-E: combination of melarsoprol and eflornithine; M-N: combination of melarsoprol and nifurtimox.
n/N: n = number of patients experiencing treatment failure, N = total number of patients.
RR: risk ratio.
T2: absence of parasite in CSF; T+: presence of parasites in CSF.
NS2: absence of neurological sings, NS+: presence of neurological sings.
Age and WBC/mL categories were defined according to Mumba Ngoyi D. et al. [8].
doi:10.1371/journal.pntd.0002088.t003
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the current follow-up of two-years would not only have the
advantage of reducing the number of lumbar punctures, but would
also potentially increase the compliance rate, as after 6 months a
decrease of the attendance rate has been reported [27].
In the present study, we investigated the ability of a number of
molecules associated with an advanced stage of disease at
diagnosis, as markers for treatment outcome [15].
The evaluation of IgM, B2MG, CXCL10, CXCL13, MMP-9,
ICAM-1, VCAM-1 and neopterin was performed on a first cohort
of patients (n = 97) followed after treatment. Neopterin, already
highlighted as a powerful marker to stage T. b. gambiense HAT [15],
resulted here to be the most accurate discriminator between cured
and relapsed patients, together with the chemoattractant chemo-
kine CXCL13.
The association of these molecules with the advanced stage of
HAT at diagnosis, already reported [15,19], was confirmed.
Furthermore, their high CSF concentration at baseline showed a
strong association with an increased risk of treatment failure.
When assessed during the complete follow-up, both neopterin and
CXCL13 were able to indicate the recurrence of brain disease, as
their concentration significantly increased in association with
relapse.
From a functional point of view, both markers might be
associated with the immune-pathogenesis of HAT. CXCL13 is a
chemokine involved in the recruitment of B and T lymphocytes to
the site of inflammation and its potential involvement in HAT
progression has already been proposed [19]. Neopterin is a
catabolic product of the GTP [28] known as an indicator of the
immune response activation, a central process in HAT late stage
pathogenesis [29]. However, further investigations are needed to
better understand the role of these molecules in both disease
progression and reappearance.
Neopterin was here shown to be the most accurate marker for
treatment outcome evaluation. When measured in the CSF of
HAT patients 6 months after the end of the treatment, it was able
to shorten the follow-up in 97 out of 111 S2 cured patients, thus
potentially reducing the follow-up period and the number of
lumbar punctures.
The present study has a number of limitations. In the
verification population, treatment failures were diagnosed either
based on the reappearance of the parasites in the CSF, or based on
a high number of white blood cell count (probable relapses). This
could represent a bias as white blood cells are not considered as a
gold standard for the detection of relapses, but for some patients it
was considered as a diagnostic criterion to which our markers were
compared. Interestingly, the concentration of neopterin and the
number of WBC, but not CXCL13, was significantly lower in
suspected relapses compared to confirmed relapses 6 months after
treatment (data not shown), suggesting that some physiopatholog-
ical differences may characterize the two groups.
Most relapse cases included in the present study had received
melarsoprol treatment, which was, at the moment of the study, the
first line treatment in the Democratic Republic of the Congo.
However, due to the high relapsing rate observed after melarso-
prol treatment, the first treatment of choice for T. b. gambiense HAT
has now changed to eflornithine and NECT therapies [3,4].
Deeper investigations on a multi-centric cohort including recov-
eries and failures after treatments other than melarsoprol are
needed, as already done for the counting of leukocytes [5], even if
low failure rates with NECT have been reported so far [30].
Figure 1. Kinetics of neopterin, CXCL13 and WBC during the follow-up. The variation in concentrations of the three markers in S1 cured
patients, S2 cured patients and S2 relapsing patients are represented. Median concentrations at each time point are reported. Bars represent inter-
quartile intervals. Numbers on the graphs represent the number of CSF samples assessed at each time point for each category of HAT patients. BT:
before treatment; EoT: end of treatment; 3 M, 6 M, 12 M: 3, 6, 12 months after treatment. FU: follow-up.
doi:10.1371/journal.pntd.0002088.g001
Table 4. Performances of neopterin, CXCL13 and WBC in discriminating between S2 cured and S2 relapsed patient.
Marker, Tx AUC% pAUC% Cut-Off SP% (95%CI) SE% (95%CI) LR+ LR2 TN FN
Neopterin [nmol/L]
3 M 90 69.3 17.3 57.5 (48.7–66.4) 93.3 (88.6–98.1) 2.2 0.12 65 7
6 M 93.9 75.8 27.9 87.4 (81.1–92.8) 92.2 (84.4–98.4) 7.3 0.09 97 5
12 M 98.4 93.3 41.4 97.3 (93.6–100) 94.4 (83.3–100) 35.0 0.06 107 1
CXCL13 [pg/mL]
3 M 86 60.4 58.9 52.2 (42.5–61.1) 90.5 (84.8–96.2) 1.9 0.18 59 10
6 M 92.4 69.7 53.2 64 (55–73) 90.6 (82.8–96.9) 2.5 0.15 71 6
12 M 94.7 78.3 76.7 87.3 (80.9–92.7) 94.4 (83.3–100) 7.4 0.06 96 1
WBC (Cells/mL)
3 M 87.1 64.5 14.5 62.8 (54–71.7) 90.5 (84.8–96.2) 2.4 0.15 71 10
6 M 93.3 71.4 11.5 81.1 (73.9–88.3) 90.6 (82.8–96.9) 4.8 0.12 90 6
12 M 94.4 70.9 9.5 92.7 (87.3–97.3) 94.4 (83.3–100) 12.9 0.06 102 1
3 M, 6 M, 12 M: 3, 6, 12 months after treatment.
Number of patients: 3 M cured n= 113, relapsed m=105; 6 M cured n = 111, relapsed n= 64; 12 M cured n= 110, relapsed n = 18.
*pAUC was calculated between 90 and 100% of sensitivity.
SP%= specificity%; SE%= sensitivity%.
Cut-off corresponds to the best combination of SP and SE within the pAUC.
LR+: positive likelihood ratio, LR2: negative likelihood ratio.
TN: true negatives, number of cured patients correctly classified.
FN: false negatives, number of relapsing patients wrongly classified as cured.
doi:10.1371/journal.pntd.0002088.t004
Neopterin for T. b. gambiense HAT Follow-up
PLOS Neglected Tropical Diseases | www.plosntds.org 7 February 2013 | Volume 7 | Issue 2 | e2088
Another drawback may rely in the lack of specificity of
neopterin. This metabolite has been reported to be an indicator
of the immune activation in other pathological conditions
including HIV [31,32]. However, we observed significantly lower
levels of neopterin in patients affected by cerebral malaria or
meningitis when compared to HAT patients (data not shown).
Better insights on the role of neopterin in the physiopathology of
disease relapses could be achieved through the use of animal
models, as already done for IL-10 [33].
Due to its high ability in stage determination [15], developments
for the translation of neopterin in an ASSURED test [34] for
staging are ongoing. Here we extended the potential utility of this
marker by showing its power as outcome predictor. In the present
study, different cut-offs in neopterin concentration have been
calculated, corresponding to the best performance of the marker at
each time point of the follow-up. However, to be translated into
clinical practice, a unique and highly accurate cut-off for the
interim-follow up visits as well as a cut-off for the TOC visit should
be determined, as it has been recently done for the WBC [5,8].
The reduction of the follow-up from 24 months to a maximum
of 12 months would have the major advantage of a decreased
number of lumbar punctures for patients and, as a consequence,
an increased attendance rate. However, a further improvement in
patients’ management would be the finding of test-of-cure markers
in plasma. All molecules investigated here in CSF, were also
assessed in the plasma of a small number of patients, but none of
them was able to indicate the reappearance of the disease (data not
shown).
In conclusion, the present study demonstrated the accuracy of
neopterin in predicting and detecting treatment outcome for HAT
patients. Due to its power as both staging [15] and follow-up
marker for T. b. gambiense sleeping sickness, it is a promising
candidate for further investigations in the field.
Supporting Information
Figure S1 Flow-chart describing the patients investigat-
ed for the verification analysis. BT: before treatment; EoT:
end of treatment; DE: disease evolution; 3 M, 6 M, 12 M, 18 M,
24 M: 3, 6, 12, 18, 24 months after treatment; ToC: test-of-cure. *
Patients were included according to the criteria described by
Mumba Ngoyi et al. [8]. { Patients excluded from the present
study: n = 8, presence of parasites in blood at the time of relapse;
n = 4, stage 1 relapse; n= 37, death during the follow-up; n= 46,
lost during the follow-up or missing more than one time of interim
follow-up; n= 23, insufficient CSF sample. 1 One patient was
considered cured at the end of the follow-up even if the last visit
was done 18 months after treatment. Nomenclature assigned
according to WHO/CDS/NTD/IDM/2007.1 [10].
(TIF)
Figure S2 Kinetics of the eight molecules and of WBC
assessed on the screening cohort. The variation in
concentrations of neopterin, CXCL13, CXCL10, ICAM-1,
VCAM-1, B2MG, MMP-9, VCAM-1 and IgM, as well as the
number of WBC in the CSF of S1 cured patients, S2 cured
patients and S2 relapsing patients are represented. Median
concentrations at each time point are reported. Bars represent
inter-quartile intervals. Numbers on the graphs represent the
number of CSF samples assessed at each time point for each
category of HAT patients. BT: before treatment; EoT: end of
treatment; 3 M, 6 M, 12 M: 3, 6, 12 months after treatment. FU:
follow-up.
(TIF)
Table S1 Characteristics at baseline of the screening cohort.
(DOC)
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